All In Biotech

Drug Trial Radar · NCT07224399

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Oct 9, 2025

Primary completion

Jul 17, 2026

Study completion Oct 31, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obese but otherwise healthy subjects.

Conditions

  • Healhty
  • Overweight or Obesity

Interventions

  • BGM1812Drug

    Administered SC.

  • PlaceboDrug

    Administered SC.

  • BGM1812Drug

    Administered SC.

  • PlaceboDrug

    Administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment adverse eventsTime frame: Predose up to 6 weeks (Part A) & 9 weeks (Part B)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron CPC, Inc

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.